Of six new oral cephalosporins, cefixime and cefpodoxime were the most active (MIC for 90% of isolates tested [MIC90], 16 ,ig/ml) against Bordetella pertussis, followed by cefetamet, cefprozil, and loracarbef (LY163892) (MIC90, 64 ,ug/ml) and ceftibuten (MIC90, 128 ,ug/ml). Against Bordetella parapertussis, loracarbef was more active (MIC90, 32 ,ug/ml) than the other compounds tested (MIC90s, 64 to >128 ,ug/ml). The new oral cephalosporins are unlikely to play a role in pertussis treatment.
cephalosporins are unlikely to play a role in pertussis treatment.
The older oral cephalosporins show very poor activity against Bordetella pertussis. The MICs of cephalexin, cephradine, and cefadroxil range between 31 and >128 ,ug/ml (1, 5) , and those of cefaclor range between 12 and 25 ,ug/ml (1) . Cephalexin at a concentration of 40 ,ug/ml was chosen by Sutcliffe and Abbott (9) as the selective agent in charcoal horse blood agar for clinical isolation of bordetellae, since the compound is inactive against B. pertussis but inhibitory to most organisms of the normal nasopharyngeal flora.
Cefuroxime, a parenteral extended-spectrum cephalosporin, has MICs of 1.5 to 6 ,ug/ml against B. pertussis (1). After oral administration of the new prodrug cefuroxime axetil, cefuroxime concentrations of 3.3 ,ug/ml in respiratory secretions have been measured (R. A. Walstad, J. S. Vilsvik, E. Thurmann-Nielsen, J. V. Griggs, and G. W. Brown, Proc. Cefuroxime Axetil Symp., London, United Kingdom, 1988, p. 65-67). Thus, for the first time an orally applicable cephalosporin has become of interest for the treatment of pertussis. We therefore studied the in vitro activities against B. pertussis and Bordetella parapertussis of six other new oral cephalosporins, some of which show remarkably improved activities against many fastidious and nonfastidious gram-negative bacteria (R. N. Jones, Antimicrob. Newsl. 5: [1] [2] [3] [4] [5] [6] [7] [8] 1988 ).
The test procedure was as described previously (4) . Powders of known potency of the following antimicrobial agents were supplied by the manufacturers or their distributors in the Federal Republic of Germany: cefetamet (Ro 15-8074) (Hoffmann-La Roche, Grenzach, Federal Republic of Germany), cefixime (EMD 49 653; FK-027) (E. Merck AG, Darmstadt, Federal Republic of Germany), cefpodoxime (RU 51764; R-3746) (Albert-Roussel, Wiesbaden, Federal Republic of Germany), cefprozil (BMY-28100) (Bristol, NeuIsenburg, Federal Republic of Germany), ceftibuten (7432-S) (Essex, Munich, Federal Republic of Germany), and loracarbef (LY163892) (Lilly, Bad Homburg, Federal Republic of Germany). Stock solutions at 2,000 ,ug/ml were prepared by following the manufacturers' instructions.
An agar dilution procedure patterned after the recommendations of the National Committee for Clinical Laboratory Standards (6) The susceptibilities of the Dutch B. pertussis isolates and of the two Bordetella ATCC strains were comparable to those of our local isolates, being identical to or one dilution step lower than the MIC%0s. Performance of the tests in duplicate did not show any intrastrain variations.
As far as literature data on the in vitro activities of the new oral cephalosporins against B. pertussis are available, they are similar to our results. Simon found MIC90s of >100 ,ug/ml for cefetamet (8) and 12.5 ,ug/ml for cefixime (7 In conclusion, all of the new oral cephalosporins tested are unlikely to play a role in the treatment of pertussis patients due to the poor in vitro activities of these agents against bordetellae. On the other hand, compounds that are totally inactive against bordetellae but that show high activity (comparable to the activities of parenteral broad-spectrum cephalosporins) against many constituents of the normal nasopharyngeal flora might eventually replace cephalexin as the inhibitory agent in charcoal horse blood agar. Cefetamet and ceftibuten in particular deserve further evaluation in this respect.
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